Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model





) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.2%. By the end of trading, DaVita rose $1.21 (1.2%) to $103.61 on average volume. Throughout the day, 976,783 shares of DaVita exchanged hands as compared to its average daily volume of 676,200 shares. The stock ranged in a price between $101.60-$103.79 after having opened the day at $101.99 as compared to the previous trading day's close of $102.40. Other companies within the Health Care sector that increased today were:

China Kanghui Holdings



), up 20.9%,

Prima Biomed Ltd. ADR



), up 19.5%,

Dehaier Medical Systems



), up 15.5%, and

AEterna Zentaris



), up 14.4%.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita has a market cap of $9.55 billion and is part of the

health services

industry. The company has a P/E ratio of 18.5, equal to the average health services industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 33.2% year to date as of the close of trading on Thursday. Currently there are nine analysts that rate DaVita a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates DaVita as a


. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front,

Escalon Medical Corporation


TheStreet Recommends


), down 22.4%,

MEI Pharma



), down 20.5%,

Allied Healthcare Products



), down 16%, and

Aoxing Pharmaceutical Company



), down 13.3%, were all laggards within the health care sector with




) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!

Free download now